<DOC>
	<DOCNO>NCT02198274</DOCNO>
	<brief_summary>Study evaluate anti-tumour activity , safety pharmacokinetics unlabelled sibrotuzumab administer weekly ( seven day +/- one day ) dose 100 mg ( total 12 administration ) patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Intravenous BIBH 1 Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Patients metastatic colorectal cancer International Union Against Cancer ( UICC ) Stage IV progressive least two previous chemotherapy regime refuse conventional treatment eligible conventional treatment Progressive disease document subsequent compute tomography ( CT ) magnetic resonance imaging ( MRI ) scan prior study entry . The last CT MRI scan must perform within 1 month study entry . The first CT MRI scan conduct within 6 month study entry Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 Expected survival ≥ 6 month Greater equal 18 year age Platelet count ≥ 100 x 10**9/L Total leukocyte ≥ 2500/mm**3 Alanine aminotransferase/Aspartate aminotransferase ( ALT/AST ) ≤ 4 x upper limit normal Total bilirubin ≤ 2.0 mg/dl ( 34µmol/L , Systeme International ( SI ) unit equivalent ) Serum creatinine ≤ 2.0 mg/dl ( 0.20 mmol/l ) Written informed consent accordance Good Clinical Practice local legislation Active metastatic disease central nervous system , exhibit new enlarge lesion CT MRI scan within 3 month treatment ( i.e. , surgery radiotherapy ) brain metastasis Exposure investigation agent within 30 day prior first BIBH 1 infusion Patients fully recover surgery ( incomplete healing ) Chemotherapy immunotherapy within 30 day prior first BIBH 1 infusion Radiation therapy symptomatic site include tumour measurement within 30 day prior study entry Previous administration murine , chimeric humanise measurement and/or antibody fragment ( e.g . BIBH 1 , Panorex ) Serious illness : e.g. , active infection require antibiotic , bleed disorder , patient know untreated unstable coronary heart disease ( e.g . unstable angina myocardial infarction within 6 month prior study entry ) diseases consider investigator potential interfering obtain accurate result study Women breastfeed pregnant Men woman childbearing potential unwilling utilise medically acceptable method contraception Patients suffer autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>